Physician profile
David Schlitt
NPI 1831166263
$1,527.13
in general payments reported to CMS, 2019-2025
30 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $148 · 2022: $348 · 2023: $385 · 2024: $289 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $182.14 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $149.96 | 2019-2025 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.40 | 2019-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $107.50 | 2022-2024 | Trintellix |
| Novo Nordisk INC | $101.97 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $94.53 | 2019-2024 | Shingrix, Arexvy |
| Supernus Pharmaceuticals, INC. | $90.68 | 2022-2023 | Qelbree |
| Sumitomo Pharma America, INC. | $84.60 | 2023-2025 | Gemtesa |
| Pfizer INC. | $73.14 | 2019-2025 | |
| Amgen INC. | $59.87 | 2019-2023 | Evenity, Prolia |
| Allergan, INC. | $58.61 | 2020 | |
| Astellas Pharma US INC | $56.61 | 2019-2023 | Myrbetriq |
| Jazz Pharmaceuticals INC. | $44.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.33 | 2023-2024 | |
| Amarin Pharma, INC. | $27.86 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.68 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $22.96 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.64 | 2022 | |
| Dexcom, INC. | $19.24 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $16.20 | 2022 | |
| Merck Sharp & Dohme LLC | $15.21 | 2022 | |
| Abbott Laboratories | $15.15 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $13.84 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.82 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.67 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $13.50 | 2024 | Ryaltris |
| Exact Sciences Corporation | $13.44 | 2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $13.02 | 2022 | |
| Optinose US, INC. | $12.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schlitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.